Research from Albert Einstein College of Medicine in the Area of Acute Myeloid Leukemia Published (TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells).

A recent study conducted by researchers at Albert Einstein College of Medicine has identified a potential therapeutic target for acute myeloid leukemia (AML). The study found that a protein called TMIGD2 is expressed by AML cells and plays a crucial role in the development and maintenance of the disease. Targeting TMIGD2 with monoclonal antibodies was shown to reduce leukemia burden in AML patient-derived xenograft models without affecting normal hematopoietic stem/progenitor cells. These findings provide a promising strategy for the treatment of AML. [Extracted from the article]